Harpagoside (Iridoid Glycoside · Osteoarthritis · Lower Back Pain · Anti-inflammatory)

Compound	Harpagoside
Chemical class	Terpenoid — Iridoid Glycoside (Monoterpene-derived)
CAS	19210-12-9
Primary source	Harpagophytum procumbens (Devil's Claw root, South Africa/Namibia)
Key applications	Anti-inflammatory, analgesic, osteoarthritis/lower back pain
Claim strength	Moderate
Typical form	Devil's Claw root extract standardised to harpagoside (1–3%); harpagoside isolate
Buy from Herbuno	Devil's Claw Extract Powder - Harpagophytum procumbens → Devil's claw Oil Soluble Extract - Harpagophytum procumbens →

Name origin: From Harpagophytum (Greek: harpagos = grappling hook) — referring to the plant's hook-covered fruit, used for seed dispersal. Harpagoside is the primary iridoid glycoside in Devil's Claw secondary root tubers and is the standardisation marker for commercial Devil's Claw extracts. Traditional use: Devil's Claw (Harpagophytum procumbens) has been used in traditional Southern African medicine (San and Khoi peoples) for hundreds of years for pain, fever, digestive complaints, and rheumatic conditions. It was introduced to European phytomedicine in the early 20th century and is now one of the most clinically studied European herbal medicines for osteoarthritis and lower back pain. Research trajectory: Multiple human RCTs and several systematic reviews support Devil's Claw extract (harpagoside-standardised) for osteoarthritis of the hip and knee and chronic non-specific lower back pain. The EMA has issued a well-established use Community Herbal Monograph for Devil's Claw. Harpagoside is confirmed as the primary anti-inflammatory active via NF-κB, COX-2, and iNOS inhibition. Commercial source: Devil's Claw Extract Powder and Oil Soluble Extract from Herbuno. See sourcing options below.

---

Evidence for Harpagoside Applications

Osteoarthritis — hip and knee: Multiple human RCTs with Devil's Claw extract (standardised to 50–100 mg harpagoside/day) demonstrate significant improvements in pain scores, mobility, and quality of life in hip and knee osteoarthritis patients. Effect sizes are comparable to low-dose NSAIDs in some comparisons. A systematic review (Gagnier et al.) confirmed analgesic and anti-inflammatory efficacy. EMA Community Herbal Monograph supports traditional use for relief of minor articular pain. Claim strength: Moderate (multiple RCTs; comparative NSAID data).

Chronic non-specific lower back pain: Two human RCTs (Chrubasik et al.) using Devil's Claw extract (delivering 50–100 mg harpagoside/day) demonstrated significant reduction in lower back pain intensity scores and improved spinal mobility over 4–8 weeks. One RCT showed comparable efficacy to 12.5 mg rofecoxib (a COX-2 inhibitor). Claim strength: Moderate.

Anti-inflammatory mechanisms: Harpagoside inhibits NF-κB activation, reduces COX-2 and iNOS expression, and decreases TNF-α, IL-6, and IL-1β production in macrophage models. Also modulates prostaglandin E2 synthesis via both COX-dependent and COX-independent pathways. The multi-target anti-inflammatory mechanism is considered to underlie the clinical analgesic efficacy. Claim strength: Moderate.

---

Dosage & Formulator Specification

Clinical dose range from RCTs: 50–100 mg/day harpagoside (as Devil's Claw root extract). Lower back pain RCTs used 60 mg/day; osteoarthritis RCTs used 60–100 mg/day. With a 1% harpagoside extract, 6–10 g extract/day would be required — hence commercial products typically use 2–3% standardised extracts allowing 2–3 g/day extract to deliver effective harpagoside doses. Devil's Claw Extract Powder and Oil Soluble Extract are commercially available — request HPLC-verified harpagoside content on CoA. Harpagoside is more concentrated in the secondary root tubers than the primary root — specify secondary storage root origin for highest harpagoside content. Harpagoside is water-soluble as a glycoside; compatible with tablet, capsule, and aqueous liquid formats. Devil's Claw should be taken with food (reduces gastric side effects).

---

Frequently Asked Questions — Harpagoside

How does Devil's Claw compare to NSAIDs for joint pain?
Human RCTs have demonstrated that Devil's Claw extract delivering 50–100 mg/day harpagoside provides meaningful pain relief comparable to low-dose NSAIDs (rofecoxib 12.5 mg in one RCT) for lower back pain, with a more favourable GI side effect profile. However, Devil's Claw is not as rapidly acting as NSAIDs — the clinical benefit typically emerges over 2–4 weeks of consistent use. It is most appropriately positioned as a complementary approach to joint health management rather than as a pharmaceutical NSAID substitute.

What part of Devil's Claw is used for harpagoside?
The secondary storage root tubers of Harpagophytum procumbens contain significantly higher harpagoside concentrations than the primary root or aerial parts. Harpagoside content in secondary tubers typically ranges 1–3% — commercial extracts specify which root part is used. Wild harvested secondary tubers from Namibia and South Africa are the primary commercial source. Sustainable harvesting practices are important — H. procumbens is wild-harvested and is subject to CITES trade monitoring.

Does harpagoside interact with blood thinners or diabetes medications?
Devil's Claw has mild platelet aggregation inhibitory effects (harpagoside mechanism) which may theoretically potentiate anticoagulants. Formulators should include standard advisory language for individuals on warfarin or antiplatelet medications. Some case reports suggest possible blood glucose lowering activity — advisory language for insulin-dependent diabetics is appropriate. No pharmacokinetic drug interaction studies are available; advisory language is based on mechanism and case reports.

Is Devil's Claw safe for long-term use?
Clinical trials up to 12 weeks have not identified significant safety concerns at standard doses (50–100 mg/day harpagoside). Long-term use beyond 12 weeks has not been specifically studied in controlled trials. EMA Community Herbal Monograph approves traditional use for articular pain relief. Contraindicated in active gastric or duodenal ulcers due to secretagogue activity (stimulates gastric acid secretion at higher doses). Standard pregnancy and breastfeeding advisory applies.

Related compounds: Aucubin, Catalpol, Geniposide, Borneol

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery